20 May 2021
In an attempt to demonstrate technology that distinguishes between single base errors in DNA, NunaBio Ltd. have tested their enhanced signal technology using DNA sequences associated with colorectal cancer.
It is of interest to understand the nature of microsatellite instabilities (MSIs) which can cause disease such as colorectal cancer (CRC). The sequence we studied is very similar to the mononucleotide tandem repeat sequences found within the BAT25 locus, a poly-T repeat unit where a build-up of errors in the number of T bases can predispose to CRC.
We recently demonstrated in our labs that our enhanced fluorescence sensor platform can distinguish between mononucleotide repeats of 9, 10 and 11 T bases. Being able to distinguish between sequences, on a surface and in a single experiment, that only differ by one or two bases is of interest for future rapid genetic sensors.
The figure below compares a standard detection method (grey) with NunaBio's enhanced sensing (blue). The standard method shows little difference in signal intensity, whether a sample is hybridised to a complementary sequence or to sequences with one or more base mismatches. In contrast, NunaBio's method gives a consistently higher signal intensity than the standard method, and the intensities produced by different sequences can be distinguished.
Working with NunaBio
We work through detail design, integration and initial testing, repeating this process to optimise the design before verification testing.
Our work is fully documented and a package of data and specifications can be assembled to allow scale up manufacture to start smoothly.
We have extensive experience in Process Validation, Project Management to Phase 2 Manufacturing Criteria, Change Management and Quality Assurance to Regulatory standards (MHRA; FDA).
Our operations management is led by a Lead Auditor qualified in Quality Management (ISO9001), Medical Devices (ISO13485), Laboratory Testing (ISO17025), Information Security (ISO27001), and Environmental Management (ISO14001).Let's talk